ACI's 5th Annual "Big Four" Pharmaceutical Pricing Boot Camp

Constance A. Wilkinson, Member of the Firm, will Co-Chair this conference and join a panel discussion titled "Effectively Managing the Solicitation Process and Working With the Contracting Office."

Topics include:

• Understanding the terms of the solicitation and the obligations imposed by FAR regulations incorporated into the agreement
• Developing SOPs for dealing with the administrative requirements imposed by the FAR regulations
• Identifying the correct forms that must be completed and completing them properly
• Pre-award pricing disclosures
• Negotiating who is a "comparable customer"
• Gathering the information the manufacturer will need to provide during the course of the solicitation process
• Determining when a contract needs to be modified what is expected when a modification is submitted?
• Developing a roadmap for VA FSS pharmaceutical contract negotiations
• How has the contracting offi ce evolved over the past year
• What best practices would the contracting office like to see manufacturers employ?
• What changes, if any, is the contracting office contemplating since the restructuring took place?

Benjamin S. Martin, Member of the Firm, will join a panel discussion titled "Managing the Implementation and Operational Challenges Resulting from Significant Changes to the 340B Program."

Topics include:

• Purpose and function of the 340B program
• Identifying 340B "covered entities" and "new" covered entities created under PPACA
• Eligibility for new entities
• Validating the eligibility of purchasers best practices for monitoring HRSA data
• Distinguishing 340B sales from non-340B sales made to entities that fill both types of prescriptions
• Managing the accrual uncertainty created by the expansion of the 340B program
• Restrictions for participating covered entities
• Understanding 340B pricing
• Treatment of 340B sales in other federal drug pricing calculations
• Adjusting PHS prices if and when prices are restated for Medicaid rebate purposes
• Understanding how the new URA cap at 100% of AMP can still result in penny pricing and making system adjustments to capture this type of penny price
• Recalculating the PHS price for "line extension" products
• What obligations do manufacturers have to ensure that PHS pricing is available to covered entities?
• Preventing double dipping by entities that participate in both 340B and GPO contracts
• Update on the proposed rule for auditing processes and dispute resolution  

For more information, visit the American Conference Institute website.